Mousab Tabbaa, MD
Gastroenterology · Westlake, OHNPI 1184642050
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (48.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Madrigal Pharmaceuticals at 56.6% of the total. 2025 is the largest year on record at $68,106, 4.5 times the $15,262 reported in 2019. Among gastroenterology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 173 payments — averaging $787.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$77K
- Takeda Pharmaceuticals U.S.A., Inc.$31K
- Sanofi$13K
- Phathom Pharmaceuticals, Inc.$5K
- Pfizer$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- plus $6K from 30 others
Across 275 payments — averaging $4677.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$254K
- GSK$254K
- Braintree Laboratories, Inc.$233K
- Madrigal Pharmaceuticals$182K
- Astrazeneca UK Limited$144K
- F. Hoffmann-la Roche AG$56K
- plus $164K from 8 others
What the payments were for
- Consulting fees$4,1163%
- Speaking & faculty fees$54,31040%
- Grants$66,00048%
- Travel & lodging$5,8524%
- Food & beverage$5,9574%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Madrigal Pharmaceuticals | 12 | $77,047 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $31,321 |
| Sanofi | 10 | $13,093 |
| Phathom Pharmaceuticals, Inc. | 8 | $4,796 |
| Pfizer | 14 | $2,747 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $1,500 |
| AbbVie | 40 | $1,346 |
| Adare Pharmaceuticals, Inc. | 5 | $1,244 |
| Regeneron | 2 | $668 |
| Gilead | 15 | $264 |
| Johnson & Johnson | 2 | $257 |
| Janssen Scientific Affairs, LLC | 2 | $229 |
| Boston Scientific | 2 | $224 |
| Medtronic(2 entities) | 2 | $201 |
| Ipsen Biopharmaceuticals, Inc | 1 | $147 |
| Intercept Pharmaceuticals, Inc. | 1 | $124 |
| Sirtex Medical Inc | 1 | $121 |
| QOL Medical, LLC | 1 | $112 |
| Shionogi Inc | 1 | $110 |
| Evoke Pharma, Inc. | 1 | $96 |
| Merck | 4 | $71 |
| Apollo Endosurgery US Inc | 1 | $69 |
| Nestle Healthcare Nutrition Inc. | 4 | $65 |
| Amgen | 4 | $61 |
| Aimmune Therapeutics, Inc. | 3 | $60 |
| Fresenius Kabi USA, LLC | 2 | $36 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Ironwood Pharmaceuticals, Inc | 1 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Organon | 1 | $23 |
| Redhill Biopharma Inc. | 1 | $23 |
| Celltrion USA Inc. | 1 | $21 |
| Mirum Pharmaceuticals, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $18 |
| Bristol Myers Squibb | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$136,234 in reported general payments places this provider in the 95th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VoqueznaVonoprazan Fumarate | 17 | $11,708 |
| Ursodiol | 13 | $4,109 |
| Omeprazole | 98 | $1,612 |
| Pantoprazole Sodium | 54 | $555 |
| Dicyclomine Hcl | 18 | $539 |
| Amitriptyline Hcl | 13 | $114 |
| Nortriptyline Hcl | 11 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Phathom Pharmaceuticals, Inc.Voquezna | $4,796 | $11,70817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 657 gastroenterology providers in Ohio.
Other gastroenterology in Westlake
- Naim AlkhouriWestlake$1.9M
- Mohamed NaemWestlake$708K
- Rinjal BrahmbhattWestlake$92K
- Kimberly HarrisWestlake$70K
- Michael SpringerWestlake$68K
- Preeti JhawarWestlake$42K
- Pierre GholamCleveland$1.6M
- Anita AfzaliCincinnati$798K
- Kara de FeliceCincinnati$427K
- Tasos ManokasColumbus$411K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.